Chapter 11

Virus like particles: fundamental concepts, biological interactions, and clinical applications

Candace Benjamin*, Olivia Brohlin*, Arezoo Shahrivarkevishahi and Jeremiah J. Gassensmith
Department of Chemistry and Biochemistry, University of Texas at Dallas, Richardson, Texas, United States

11.1 Introduction

Nanotechnology has offered hopes for the delivery of new technologies in medicine and drug delivery, yet a growing number of voices have begun to express skepticism that these long sought advances may have been over promised. Specifically, issues with targeting and delivering payloads have been called out as being difficult obstacles that still need to be overcome. The reasons for these shortcomings are multiple and linked to issues with biocompatibility, bioaccumulation, and pharmacokinetics, all of which can be addressed through clever materials chemistry and bioengineering. The present and persistent issue in nanotech, we must remember, is the “tech” and not the “nano.”

Nature has very effectively employed nanoscale delivery vehicles for highly selective and targeted gene delivery in the form of viruses. Indeed, their efficacy in delivering sickness to people has created some skepticism to their use, but recent efforts to chemically and biologically engineer “virus-like particles” (VLPs) that take structural cues from these natural nanoparticles have begun to yield important new medicines. For instance, one oncolytic viral nanoparticle has made it to the clinic and is saving lives, but many more are in the FDA’s approval pipeline and even more are active targets of research for delivery, imaging, stimulation, and biosensing applications. Viral capsids are extremely useful for these applications as they are easy to produce and straightforward to employ. This is simply owing to the biological nature of the VLP, which imbues five major aspects that define the capsids’ value in these fields: (1) ease of production, (2) ability to self-assemble, (3) facile modification, (4) biocompatibility, and (5) immunogenicity. To date, more than 30 different VLPs have been generated through the removal and replacement of the natural viral genome with a modified set of genetic material. These “stripped down” versions spontaneously assemble in noninfectious analogs of their viral parents that lack an ability to self-proliferate while preserving many of the other native viral traits. VLPs, typically 15–400 nm, can be replicated and purified from many heterologous expression systems such as bacteria, plants, and yeast to produce ready-to-use nanoparticles for further modification. These methods of replication allow for the scalable production of uniform VLPs with a narrow size distribution, which is crucial for medical applications. These characteristics permit more precise loading of cargos inside of the carrier and regularly spaced functional handles, most commonly lysines, tyrosines, glutamates, aspartates, and cysteines for the development of a multifunctional nanocarrier (Table 11.1). Multiple conjugates can also be attached as a cargo to VLPs, thanks to the multivalency of these subunits that make up the virus including bimodal imaging agents, targeted biosensors, and shielded drug carriers. Biodistribution studies have been performed using a few of the icosahedral VLPs, which show the particles mostly accumulate in the liver and spleen and are usually cleared within 24 h. These carriers can be further modified to help determine their in vivo fate by installing moieties designed to alter the surface charge of the particle or stealth capability.

* These authors contributed equally to this manuscript.
<table>
<thead>
<tr>
<th>Residue</th>
<th>Chemical reaction</th>
<th>Incorporated material</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y85</td>
<td>Diazotization</td>
<td>Diazonium salt, 16 FAM-SE, 17 [18F]-benzaldehyde, 18 Gd(III) complex 19</td>
</tr>
<tr>
<td></td>
<td>Potassium ferricyanide–mediated oxidative coupling</td>
<td>Gold NPs 20</td>
</tr>
<tr>
<td>T19pAF</td>
<td>NaIO₄-mediated oxidative coupling</td>
<td>AF 488, 21 DNA, 21 DNA aptamers, 22 fibrin, 23 peptides, 24 PEG, 25 porphyrin 26</td>
</tr>
<tr>
<td></td>
<td>Photolysis/coupling with aniline groups</td>
<td>DNA 27</td>
</tr>
<tr>
<td>N87C</td>
<td>Thiol-maleimide</td>
<td>AF 488, 22, AF 680, 23 DOTA, 25 AF 350, 26 Oregon Green 488, 26 Gd(III) complex, 28 Taxol 29</td>
</tr>
<tr>
<td>K106, K113, N-terminus</td>
<td>Isothiocyanate coupling</td>
<td>PEG 17, TREN-bis-HOPO-TAM ligand 19</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Residue</th>
<th>Chemical reaction</th>
<th>Incorporated material</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y139</td>
<td>Diazotization and oximation</td>
<td>Diazonium salts and alkoxyamines 41</td>
</tr>
<tr>
<td></td>
<td>Iodogen method</td>
<td>Na¹²⁵I 41</td>
</tr>
<tr>
<td></td>
<td>Diazotization/CuAAC</td>
<td>Gd(DOTA) 32,33 Tn antigen, 34 pyrene PEG, 35 RGD peptide, 36 β-cyclodextrin, 37 oligoaniline 40</td>
</tr>
<tr>
<td>E97, E106</td>
<td>Amide formation/CuAAC</td>
<td>PEG 42</td>
</tr>
<tr>
<td></td>
<td>Amide formation</td>
<td>Amines 43</td>
</tr>
<tr>
<td>S123C</td>
<td>Maleimide coupling/CuAAC</td>
<td>Maleimide derivatives of alkynes followed by azido bearing Tn antigen, 44 maleimide derivatives of thiol-reactive chromophores 45,46</td>
</tr>
<tr>
<td>PAG (S123C mutant)</td>
<td>Potassium ferricyanide–mediated oxidative coupling</td>
<td>o-aminophenols or o-catechols 41</td>
</tr>
<tr>
<td>VLP</td>
<td>Targets</td>
<td>Function</td>
</tr>
<tr>
<td>-----</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>K2, K13, K16, N-terminus</td>
<td>Acylation/CuAAC</td>
<td>Tn antigen, bovine serum albumin, fluorescein, triple-sulfated ligand, AF 488, AF 568, human holo-transterrin, poly(2-oxazoline), PEG-C₆₀, oligomannosides, LacNAc, BPC sialic acid, GdDOTA</td>
</tr>
<tr>
<td>M16HPG</td>
<td>CuAAC</td>
<td>Oligomannosides</td>
</tr>
<tr>
<td>T93AHA</td>
<td>CuAAC</td>
<td>RGD-PEG, biotin</td>
</tr>
</tbody>
</table>

**P22**

<table>
<thead>
<tr>
<th>S39C</th>
<th>EDC/NHS</th>
<th>Mn porphyrin</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ATRP</td>
<td>AEMA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>K118C</th>
<th>ATRP</th>
<th>THMMA</th>
<th>Bortezomib</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Thiol-maleimide</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CUAAC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| T183C, M338C, C-terminus | Thiol | MIANS, HIV-TAT CPP, mCherry | | |

**CPMV**

<table>
<thead>
<tr>
<th>K34, K38, K82, K99, K199</th>
<th>CUAAC</th>
<th>Peptides, folic acid, fluorescein-PEG, transferrin, GD-DOTA</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EDC/NHS</td>
<td>OG 488, AF 568, AF 555, AF647, PEG, ferrocene, peptides</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>R82C, A141/163C</th>
<th>Thiol-maleimide</th>
<th>Proteins</th>
<th></th>
<th></th>
</tr>
</thead>
</table>

AEMA, Aminoethyl methacrylate; AF, Alexa Fluor; CuAAC, copper-catalyzed azide alkyn 1,3-dipolar cycloaddition; MIANS, 2-(4'-maleimidylaminino) naphthalene-6-sulfonic acid; PEG, Poly(ethylene glycol); RGD, arginyl-glycyl-aspartyl; THMMA, tris(hydroxymethyl)methylacrylamide.
as a means of controlling uptake. This ability to further functionalize VLPs allows researchers to go one step further than simply improving capsid stability through the use of groups like polyethylene glycol (PEG); it allows the design of smarter delivery vessels that can be targeted to specific cell types\textsuperscript{99,100} or introduce stimuli responsive release.\textsuperscript{91,92} Recently, more focus has been placed on understanding the immunogenicity\textsuperscript{92,93–95} of these particles and employing them to treat aggressive diseases.\textsuperscript{14,15} Their application as vaccines is plausible considering their small size and ability to illicit an immune response via their repetitive epitope display\textsuperscript{95} that also shows promise as an innate adjuvant. With these characteristics in mind, this chapter highlights the advantages VLPs offer to biomedical applications. Each of the aforementioned characteristics affords VLPs the ability to overcome limitations associated with current state-of-the-art technologies. Because most research has been focused on developing VLPs for imaging, sensing, and drug delivery applications, overviews of these areas will be presented to demonstrate the characteristics of VLPs that provide specific advantages over traditional systems. It is worth mentioning that VLPs are relatively easy for the nonbiologist to produce and require only a small investment in equipment. A number of detailed protocols, including video protocols, exist and are worth reviewing.\textsuperscript{96–99}

### 11.2 Imaging applications

VLPs are biocompatible macromolecules that bring many advantages to imaging applications. The monodisperse and multivalent coat proteins that make up the VLP contain repeating functional handles from lysine, cysteine, aspartate, glutamate, and tyrosine residues that can be used in bioconjugation reactions to attach imaging agents to the virus.\textsuperscript{100} The monodispersity of the coat proteins allows for uniformly spaced attachment of many imaging agents to each VLP for improved resolution.\textsuperscript{101} Furthermore, the multivalency of the coat proteins allows for the utilization of a second functional handle that can be used to attach a targeting ligand orthogonally for improved localization of the imaging agent in a desired region of the body.\textsuperscript{80} In certain contexts, these attributes make VLPs attractive alternatives to hard nanoparticles, which tend to bioaccumulate and have limited surface chemistry for functionalization.\textsuperscript{102} They also offer atomistically precise surfaces for functionalization in contrast to polymeric systems, which are polydisperse and have spatially disordered functional handles. The proteinaceous makeup of the VLP can help make conjugated synthetic and inorganic imaging agents more biocompatible improving the ability of these agents to translate into in vitro and in vivo studies.\textsuperscript{103} Additionally, VLPs come in different shapes and sizes that can be selected for longer retention times which allow for higher accumulation in the desired area and can extend imaging time.\textsuperscript{103} For instance, isotropic VLPs can endure longer circulation times, whereas anisotropic VLPs can avoid phagocytosis by macrophages. Additionally, larger VLPs have been shown to accumulate in tumors because of the enhanced permeation and retention (EPR) effect. These characteristics make VLPs good candidates for next-generation imaging applications.

In this section, we will highlight VLP-based imaging platforms focusing on fluorescence and magnetic resonance imaging (MRI). These two areas of imaging specifically have drawn the interest of many research groups who work with VLPs. Through their work, they have been able to increase the brightness and localization of fluorescent probes as well as increase the relaxivity rates of commonly used lanthanide-based contrast agents. A few examples of these advances in imaging technology are discussed in the following section.

#### 11.2.1 Fluorescent and optical probes

One of the earliest applications of VLPs in biotechnology was to use them as fluorescent nanoparticles for cell imaging. By attaching fluorescent dyes to the multivalent surface of a VLP, the local density of the small molecule fluorophores creates brighter imaging agents for higher-resolution imaging.\textsuperscript{100} Furthermore, by reacting at specific sites on the protein that are physically separated in space, collisional quenching between adjacent fluorophores can be avoided, thereby improving the brightness of the nanoparticle. Small molecules can be conjugated to VLPs through a variety of high-yielding bioconjugation reactions.\textsuperscript{100} For instance, EDC/NHS chemistry can be used to attach small molecules to lysine residues, diazonium coupling for tyrosine residues, carbodiimide chemistry for glutamate residues, and maleimides for cysteine residues.\textsuperscript{104} More recently, “rebridging reactions” on VLPs have made the disulfide bridge an amenable functional handle.\textsuperscript{105}

Some of the first work done on creating fluorescent VLPs for in vitro imaging applications came out of the Manchester group. Lewis et al. attached\textsuperscript{106} 120 Alexa Fluor 555 molecules to each CPMV (cowpea mosaic virus) without any self-quenching of the fluorophores. This conjugate was determined to be much brighter compared with conventional imaging agents made from polystyrene nanospheres carrying the same dye—demonstrating a practical benefit over polymeric systems. Because the multivalency of the VLP coat proteins allow for the attachment of a dye to one functional handle and a targeting ligand to another,\textsuperscript{107} it is possible to make bright targeted probes using two-relatively straightforward chemical reactions. For example, Carrico et al. demonstrated\textsuperscript{108} that
M13 phage could be modified with both Alexa Fluor 488 and antibody fragments to epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) to target imaging of breast cancer cells for diagnostic applications (Fig. 11.1). In vitro studies demonstrated the selective uptake of the targeted VLPs in cells expressing EGFR or HER2 by flow cytometry as well as localized fluorescence of the VLP conjugate in these cells by confocal microscopy. This works provides a very strong example of how targeted VLPs can be used in high-resolution fluorescence imaging.

VLPs come in different shapes, sizes, and charges that can be selected for and employed as a targeting function for the imaging agent. For instance, positively charged VLPs encourage cell uptake;65 larger VLPs are more likely to accumulate in tumors due to the EPR effect,109 and elongated VLPs avoid phagocytosis by macrophages.110 Bruckman et al. utilized32 the elongated rod shape of the plant viral nanoparticle, tobacco mosaic virus (TMV), to target vascular cell adhesion molecule (VCAM)-1 for imaging of atherosclerosis. The elongated shape (300 × 18 nm) of the VLP enhances the ability of the nanoparticle to bind to the flat walls of the arteries displaying VCAM-1.

As this technology matures, new chemistries are demanded to increase the number of fluorophores and conjugate handles for targeting ligands to help increase the scope and utility of VLPs. For instance, recent work from Chen et al. established105 a high-yielding method to conjugate a variety of dibromomaleimide handles to the disulfide bonds that bridge the pores of the VLP Qβ. Disulfides are typically structurally vital to protein tertiary structure, but Chen’s approach effectively retained the covalent bond character. Furthermore, the resulting five-membered ring that bridges the disulfide is itself fluorescent. The resulting dithiomaleimide cores are modestly bright yellow fluorophores, which allow the conjugates to be imaged in vitro (Fig. 11.2) while concurrently allowing for additional functional handles or PEG chains.

In conclusion, the conjugation of fluorescent dyes to the VLP capsid can improve the resolution of fluorescent imaging due to the high loading capabilities and monodisperse display of the dye on the VLP. Similarly, the same characteristics of the VLP capsid can be exploited to obtain high contrast MRI. In the next section, we will discuss some of the advantages VLPs offer for MRI contrast agents.

11.2.1.1 Contrast agents

Contrast-enhanced MRI is an imaging technique that uses contrast agents to greatly exacerbate the relaxation of water molecules compared with their environment making them appear either very bright (T1 contrast) or very dark (T2 contrast). Paramagnetic contrast agents, such as gadolinium (Gd3+) ions, are commonly used to increase contrast (T1) by altering relaxation times.111 How well a given contrast agent works is related to a number of physical phenomena, one of which can be altered by simply attaching the small molecule to something very large. Large macromolecules, like VLPs, have slow rotational dynamics in solution compared with small molecules.112-114 Quite generally, though exceptions exist, there is an inverse relationship between the rate of rotational dynamics (rotational correlation time) and the relaxation rate (relaxivities) denoted as

\[ T_1 = \frac{1}{r_1} = \frac{1}{r_1^{\text{ionic}}} + \frac{1}{r_1^{\text{particle}}} \]

where \( r_1^{\text{ionic}} \) is the relaxation rate due to the ionic environment and \( r_1^{\text{particle}} \) is the relaxation rate induced by the particle. This relationship is often used to explain the increased relaxivity of large particles compared with small molecules. For example, the increased relaxivity of large particles compared with small molecules is often attributed to the slow rotational dynamics of the particle, which leads to a decrease in the rate of rotational correlation time. This is particularly true for VLPs, which have slow rotational dynamics in solution compared with small molecules.

In summary, the conjugation of paramagnetic contrast agents to VLPs can significantly increase the relaxivity of the contrast agent, leading to improved imaging contrast and resolution. This is particularly true for VLPs, which have slow rotational dynamics in solution compared with small molecules.

Additionally, the large size of VLPs can be harnessed to slow the tumbling rate of contrast agents to improve MRI resolution. Prasuhn et al. conjugated21 223 Gd(DOTA) molecules to the exterior surface of CPMV and 153 to the exterior surface of Qβ. This resulted in a doubling of the relaxivity of Gd as compared with the FDA-approved Magnevist MRI contrast agent. The improved relaxivity is attributed to the limited rotational movement and diffusion associated with large VLPs. Similarly, Liepold et al. utilized111 the large size of the 28 nm cowpea chlorotic mottle virus (CCMV) to conjugate up to 360 Gd(DOTA) to the exterior lysines on each capsid for a slowed tumbling rate and improved \( r_1 \) and \( r_2 \) relaxivities as compared with free gadolinium ions (Fig. 11.3).

Another method to improve the effectiveness of contrast agents is to incur rigidity within the chelated Gd3+. This can be achieved by conjugating Gd(DOTA) to a functional handle on a VLP. Bruckman et al. found33 that Gd(DOTA) conjugated to the tyrosine residues on the surface of TMV-improved relaxation threefold compared with free Gd(DOTA) and twofold when conjugated to the glutamate residues on the interior surface (Fig. 11.4). According to the authors, conjugation to the tyrosine residues offered higher rigidity compared with the more flexible carboxylic acids from the glutamate residues, which correspondingly enhanced the Gd(DOTA) relaxivity, though an alternative explanation might also include the slower water diffusion through the internal pore of TMV.

The multivalent functional handles on the VLP also allow for the conjugation of a targeting ligand for localization of the contrast agents in a specified region of the body. Hu et al. created216 a TMV bimodal imaging agent that targeted prostate cancer cells. To do so, Cy7.5 and Dy(DOTA) were conjugated to the interior glutamate.
The N-terminus of phages was conjugated to fluorophores. The phage-displayed antibodies targeted breast cancer cells by recognizing epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2). It is shown in (A) that the phage–fluorophore conjugate was able to specifically recognize the EGFR and HER2 epitopes as determined by flow cytometry. It is shown in (B) that the phage–fluorophore conjugate targets breast cancer cells with the EGFR or HER2 for visualization by confocal microscopy. Reproduced with permission from Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks JD, Chokhawala H, Clark DS, Francis MB, N-Terminal labeling of filamentous phage to create cancer marker imaging agents. ACS Nano 2012;6(8):6675–6680.

FIGURE 11.3  The relaxivities of “free” gadolinium ions (GdCl₃) are compared with gadolinium ions conjugated to the VLP cowpea chlorotic mottle virus. (A) shows the attachment of Gd. The triangles represent the free Gd, and the squares represent the conjugated Gd. (B) shows the $r_1$ values, and (C) shows the $r_2$ values. It is clear from both (B) and (C) that the conjugated gadolinium ions have higher relaxivities suggesting that the slowed tumbling rate improves the efficacy of the contrast agent. Reproduced with permission from Liepold L, Anderson S, Willis D, Oltrogge L, Frank JA, Douglas T, Young M. Viral capsids as MRI contrast agents. Magn Reson Med 2007;58(5):871–879.

FIGURE 11.4  Gd(DOTA) is attached to the exterior tyrosine residues to form (eGd-TMV) and interior glutamate residues to form (iGd-TMV). The attachment sites are highlighted in (A). At 60 MHz, the slope of eGd-TMV shown in plot (B) gives an $r_1$ value of 18.4 mM/s which is threefold higher than free Gd(DOTA) (4.9 mM/s at 60 MHz). At 60 MHz, the slope of iGd-TMV shown in plot (C) gives an $r_1$ value of 10.7 mM/s which is twofold higher than free Gd(DOTA). These plots suggest incurred rigidity of the Gd(DOTA) after conjugation to the VLP with the highest rigidity and relaxation values when conjugated to the exterior tyrosine residues. Reproduced with permission from Bruckman MA, Hern S, Jiang K, Flask CA, Yu X, Steinmetz NF. Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents. J Mater Chem B 2013;1(10):1482–1490.
residues of TMV for NIR imaging and MRI. PEG and DGEA were conjugated to the tyrosines on the exterior surface for a biocompatible probe that specifically images prostate cancer.

Another bimodal imaging agent using TMV was designed by Dharmarwardana et al. in which FITC was conjugated to the exterior tyrosine residues for fluorescence imaging and TEMPO was conjugated to the interior glutamates for MRI (Fig. 11.5). Uniquely, this MRI probe is also a superoxide sensor as the organic radical contrast agent, TEMPO, is reduced in in vitro and in vivo environments into an MRI silent state, but upon oxidation by superoxide, it functions as a “turn on” MRI sensor. This allows the sensor to “turn on” in \( T_1 \) and \( T_2 \) weighted imaging. The reduced state is MRI inactive, showing up as dark \( (T_1) \) or light \( (T_2) \), while the oxidized state is MRI active. This sensor can be used to show areas of high concentrations of superoxide, which exist in certain injury states. In the following section, the use of VLPs in sensor applications is discussed.

11.3 Virus-based sensors

Development of biological detection systems has received a considerable amount of attention in the biomedical field owing to its vital importance in clinical diagnosis and treatment. However, many available biosensors such as enzyme, cell-based, electrochemical, and color-based sensors suffer from limited sensitivity, selectivity, reliability, simplicity, and stability to detect and identify biological targets with high levels of certainty. \(^{116-118}\) Accordingly, there is a pressing need for the invention of advanced biorecognition probes to overcome these challenges. VLPs have been employed as a sensing platform, thanks to their ease of synthetic and genetic modification to their coat proteins, which can be used to enhance the binding affinity for specific targets to solve selectivity and sensitivity problems. Moreover, by strategically engineering or functionalizing the multivalent surface of a viral capsid, these particles are able to detect multiple analytes such as proteins, DNA, virus, antibodies, etc. Because VLPs are monodisperse, they allow the attachment of precise and high amounts of target analytes to the capsid giving high accuracy, rapid detection, and significant response to signal amplification. In the following sections, we will review some examples of different virus-based sensors.

### 11.3.1 Enzyme-based biosensors

An enzyme-based biosensor is an analytical tool that detects changes in the enzymatic activity of a substrate. Therefore, the presence of high amounts of enzyme as a molecular recognition element can enhance response signal toward the target molecule, resulting in a highly sensitive sensor with a short detection time. Moreover, using highly specific enzymes toward the desired target allows for enhanced selectivity of the sensor. At present, there are several examples of selective and sensitive enzyme...
biosensors, such as the glucose biosensor that generally uses glucose oxidase (GO) to catalyze oxidation of β-D-glucose. Although these sensors are selective, they suffer from instability, high detection limits, and high production costs. These limitations result from poorly absorbed enzymes, environmental changes (pH and temperature), low enzyme activity, and low signal detection.

To address these problems, there are several reports on integration of available probes with VLPs. A recent example is coupling, the enzyme modified TMV to a Pt sensor chip for amperometric detection of glucose. For this purpose, a streptavidin-conjugated glucose oxidase ([SA]-GOD) complex was immobilized on the surface of biotinylated TMV through biotin affinity binding. The functionalized TMV was loaded on the Pt electrode which caused a significant increase in enzyme density on the surface of the sensor chip. The result is higher glucose signal, lower detection limit, and high enzyme activity.

Additionally, VLPs can be used as a specific sensing platform for β-galactosidase. Nanduri et al. has shown that the filamentous bacteriophage lG40 has high binding affinity to galactosidase which can be used for sensitive and specific detection of this enzyme. They immobilized IG40 on a gold surface of SPR SPREETATM sensor chip and compared the sensor performance with an F8-5 as a control phage (nonspecific to β-gal). Their data showed a 10-fold enhancement in detection response compared with control phage.

Additionally, the surface of VLPs exposes thousands of identical binding sites that permit the attachment of a large number of enzymes to the viral capsid in a spatially controlled manner. Conjugated enzymes maintain their structure and catalytic activity, both of which are required for a sensitive enzyme-based probe. One example of the conjugation of enzymes to a VLP for the development of a probe was shown by Poghossian et al. In this study, they demonstrated the strong immobilization of penicillinase enzyme on TMV via biotin and streptavidin—penicillinase binding affinity. The modified TMV was loaded on Al-p-Si-SiO$_2$-Ta$_2$O$_5$ as an electrolyte insulator semiconductor to build a highly sensitive and stable biosensor (Fig. 11.6). The modified sensor is able to detect penicillin concentrations in the range of 0.1–10 mM with a 50 μM lower detection limit.

VLPs have great potential for successful integration with other sensors owing to their desirable properties such as coupling biological elements like enzymes, high thermal and chemical stability, and lack of toxicity. This will help with the emergence of novel sensors with promoted performance like the analyte detection over low concentration range, high specificity, and stability.

In addition to use of VLPs in developing the enzyme-based sensors, they can be applied as a color-based probes and use different optical techniques (fluorescence spectrometry, UV/Vis, chemiluminescence) for biomolecular interaction analysis and specific detection and identification of a variety of biological analytes. In the following section, we will show the examples of VLPs as a colorimetric sensor.

### 11.3.2 Colorimetric biosensors

Colorimetric biosensors produce human and machine-readable color changes in response to biological analytes. General drawbacks of these sensors tend to be poor selectivity and relatively low sensitivity, which limit their clinical applications; therefore, there is a need for new
architectures to enhance sensitivity toward bioanalytes. VLPs can be engineered chemically and genetically to promote intrinsic affinity toward a specific analyte. For example, Oh and coworkers introduced a selective and stable colorimetric probe for the detection of different types of antibiotics by using the self-assembly properties of a genetically engineered nonlytic M13 VLP. In this study, an M13 was functionalized with the WHW peptide to have 1000 copies of tryptophan (W) histidine (H) tryptophan (W) sequences which can act as a receptor for antibiotics. Target binding causes the quasi-ordered bundles of phage matrices to swell or shrink, which induces a change in the optical scattering properties on the chip surface following interaction with different target antibiotics (Fig. 11.7). This scattering of light results in an apparent color, even though no chromophores are present.

For early disease diagnostics, there is critical need for tools to sense and measure different biological molecules, proteins, and biomarkers on cancerous cells. To date, several colorimetric sensors such as enzyme-linked immunosorbent assay (ELISA) and cell-based ELISA (CELISA) have emerged for this purpose; however, because of the limited number of attached enzymes and high dissociation constant between antibody and antigen, their detection limit is in the nanomolar range. Recently, VLPs have offered several improved colorimetric sensing systems with higher response signals. For example, Brasino et al. improved ELISA sensing performance by dually decorating a filamentous bacteriophage Fd with antibodies for specific antigen detection and horseradish peroxidase to generate an amplified colorimetric signal. In another work, Wang et al. successfully designed a “CELISA” using a modified TMV to detect folate receptors overexpressed on cancer cells. For this purpose, the exterior surface of TMV was modified with platinum nanoparticles as a peroxidase surrogate and folic acid as a cancer cell targeting mechanism. When the modified TMV binds to cancer cells that overexpress folic

![FIGURE 11.7 Schematic illustration of colorimetric sensor composed of filamentous M13 modified with WHW peptide. (A) The self-assembly properties of M13 has been used to make liquid crystalline thin films by the pulling technique. (B) The RGB signal intensity was changed in the presence of different antibiotics at different temperatures owing to changes in the M13-based bundle nanostructure. (C) Principal component analysis (PCA) was used to show discrimination ability of the sensor for different antibiotics (cephalosporin, penicillin, and rifampin). Modified with permission from Moon JS, Park M, Kim WG, Kim C, Hwang J, Seol D, Kim CS, Sohn JR, Chung H, Oh JW, M-13 bacteriophage based structural color sensor for detecting antibiotics. Sens Actuators B Chem 2017:240, 757–762.](image-url)
acid receptors, superoxide is supplemented to provide a colorimetric indicator of which cells are cancerous. Consequently, modification of VLPs has afforded a new color biosensing system that could be used for biomedical applications and diagnostics assays. Another example is an M13 bacteriophage—DNA conjugated system that has been developed by Domaille et al. for protein detection. In this study, acyl hydrazone linkages were utilized for DNA sequence incorporation, which led to a strong and detectable change in absorption signal (410 nm) on interaction with IgG as a model protein. Thus, by using the phage as a sensing platform, they created a rapid and extremely sensitive tool for protein detection in the range of 0–1000 fmol.

11.3.3 Electrochemical biosensors

Electrochemical biosensors are involved in the generation or consumption of electrons over an interaction between biochemical receptors and an electrochemical transduction element. Although these sensors are usually selective and sensitive toward target biomolecules, they suffer from narrow temperature ranges, limited half-life, and high background signal. In recent decades, VLPs have received much attention for their thermal stability and robustness. Combining VLPs as a sensing receptor with analytical methods such as electrochemical methods can be a reliable way to simultaneously increase electrochemical sensor performance and improve sensor stability. For instance, Ghodssi and coworkers developed a novel electrochemical biosensor for Neuregulin-1 gene detection. The modified probe showed a high surface area with strong current change on DNA hybridization, which lead to an 8-fold increase in signal and 9.5-fold enhancement in biosensing performance.

Coating VLPs on the surface of electrodes is a way to increase the electrode surface area, thus allowing for a higher electrochemical signal, decreased signal to noise ratio, and greater sensitivity. For example, a new impedance sensor was developed by Zang et al. that applied FLAG-tag—modified TMV on an electrode surface by capillary action and surface evaporation for label-free antibody detection. Thus, owing to the high surface to volume ratio of TMV nanotubes and several hundred available binding sites on its surface, a high peptide density could anchor to the electrode, which maximized antibody detection.

Additionally, VLPs can be used as a sensing platform for biomarker and cancer cell detection. One example is the immobilization of a filamentous M13 phage on the surface of a modified Si$_3$N$_4$ chip by reacting the N terminal domain of the phage coat protein with an aldehyde group on the chip surface to make a light addressable potentiometric sensor (LAPS). Jia et al. showed the sensor is able to detect human phosphatase of regenerating liver-3(hPRL-3) at concentrations of 0.04–400 nM and mammary adenocarcinoma cell (MDAMB231) at concentrations of 0–105 cells/mL through specific binding to the phage, which had been evolved via phage display, and subsequent change of the output voltage of LAPS. Therefore, integration of bionanoreceptors with conventional electrochemical methods can be an effective strategy for improving sensor performance.
VLPs can act as a key component in different biosensing systems. Their potential for incorporation with different nanomaterials and analytical methods give many opportunities for scientists to expand this area of research and progress biomedical and particularly diagnostic applications. One approach is drug delivery by stimuli responsive VLPs which can show high efficacy and specificity for cargo delivery in the targeted location on sensing a particular stimulus. In the following section, we will discuss this application of VLPs.

11.4 VLPs as drug delivery vehicles

Effective drug delivery requires that the desired cargo passes several transport barriers from the site of introduction into the patient until it has reached its intended destination while avoiding off-target effects. Unfortunately, there are many barriers to successful delivery. The reticuloendothelial system hampers dosage efficacy especially if the materials have long circulation times which subsequently leads to faster clearance from the body. Additionally, cellularly targeted drugs need to permeate the membrane and avoid or survive endosomal trafficking before it releases its cargo. Several nanoscale platforms are being investigated for drug delivery as nanoparticle based therapeutics as a result of their small size and favorable pharmacokinetics, which offer solutions to many of the problems associated with conventional drug administration. Despite growing interest in their use and development, the number of FDA approved nanoparticle drugs is limited, and more than half of the formulations currently undergoing trial are liposomal. These systems have been shown to suffer from rapid and dose-dependent clearance from the body and conflicting results on the efficacy of attaching targeting ligands.

VLPs, on the other hand, are capable of accomplishing this task by carrying a diverse set of therapeutic cargos ranging from nucleic acids, genes, aptamers, therapeutic drugs, larger proteins, while still being amenable to further functionalization—some have even been cleared for use by the FDA. This paves a path for drug delivery to make further advancements through the utilization of a robust and tunable carrier to circumvent the issues plaguing current delivery methods.

11.4.1 Cargo loading

As discussed in previous sections, VLP geometries can play an important role in targeting and cell specificity. Because the shape of nanoparticles is known to alter their pharmacokinetics, the VLP geometry makes for a uniquely tunable parameter for drug delivery. For instance, small icosahedral nanoparticles diffuse well into tissues but have smaller cargo capacities while their larger, filamentous counterparts are better suited for aligning with vessel walls, though they do not infiltrate cells as well. Fortunately, many viral capsids can be modified to create a more suitably sized or shaped carrier. For example, rodlike VLPs such as TMV and M13, which use their RNA to self-assemble, can be tuned to specific sizes by adjusting the length of their RNA. Icosahedral viruses, CCMV in particular, has been shown to exhibit an increase in capsid size from 27 to 30 nm linearly as the pH is varied from 5 to 7. Asensio et al. has gone one step further and shown that a single amino acid change—S37P—changes the assembly of MS2 capsid proteins from 27 nm capsid with T = 3 symmetry to a much smaller 17 nm capsid with T = 1 symmetry. Further investigation on the effects of drug loading was performed by Cadena et al. to elucidate the effects of increasing cargo size on the formation of icosahedral VLPs. They have found that varying lengths of RNA from 140 to 12,000 nt can be completely encapsulated while causing a change in capsid size. For shorter strands, the RNA is packaged into 24 and 26 nm capsids, while a single strand of RNA greater that 4500 nt is packaged by two or more 26–30 nm capsids showing that just changing the length of the structural RNA, various lengths, and sizes of VLPs can be achieved to predetermine the cargo capacity for delivery applications. Utilizing VLPs allows for increased and precise drug loading, which remedies issues with low and inaccurate dosing. Rurup et al. have demonstrated a method of predicting the loading of VLPs using teal fluorescent proteins (TFPs) and CCMV where more than 10 3 nm TFPs can be loaded inside of the 18 nm cavity of the viral capsid (Fig. 11.9). Through the use of homo-FRET, they have determined that tethering the TLPs to the capsid proteins yields more predictive and controlled loading behavior increasing the number of fluorescent proteins from 6—in the coiled coil system—to 20 dimeric units when directly bound to the CPs. This information lays some of the ground work for further progress in the use of VLPs as a drug carrier.

11.4.2 Drug delivery

Encapsulating therapeutics within a nanoparticle offers protection from rapid clearance from the body and the harsh cellular environments that would normally degrade free small molecules before reaching their target destination. The ease of functionalization of VLPs allows for the design of smarter drug delivery vehicles including stimuli responsive release. For example, work by Chen et al. utilizes VLP Qβ, first functionalized with an azide linker on the surface exposed to NH₂, handles via EDC coupling followed by a CUAAC reaction to attach the photocleavable Dox group. The as-synthesized VLP encountered solubility issues so to remedy this, they further functionalized the surface by adding a second functional group—PEG 1K or 2K through dibromomaleimide.
chemistry. The final VLP is a soluble, low toxicity carrier that shows cytotoxicity on stimulation with UV light which cleaves the linker, activating Dox release in the cells. The Steinmetz group has also done extensive work showing that the conjugation of molecules such as Dox can be attached and successfully delivered to cells. They have made use of the VNP CPMV decorated with covalently bound Dox on the exterior surface demonstrating that the functionalized particle in low doses is more cytotoxic than free Doxorubicin and exhibits a time-delayed release. This work has also determined that the CPMV-Dox particles get trafficked to endosomal compartments, as seen in Fig. 11.10 in HeLa cells, where the proteinaceous carrier is degraded, and the drug molecules are released into the cellular environment.

11.4.3 Targeting

The addition of a targeting functionality offers several advantages over nontargeted drugs. Mainly they consist of reducing the side effects associated with damage to healthy tissues and enhancement of uptake into afflicted cells. Targeting can be approached in either a passive or active manner depending on the nature of the particle in use and the functionalities incorporated into its design. Passive targeting includes (1) the EPR effect, (2) approaches relying on the tumor microenvironment, and (3) intratumoral delivery. The EPR effect is a phenomenon where increased permeability of the tumor vasculature is combined with poor lymphatic drainage, which makes it difficult for high molecular weight carriers to be removed from the tumor environment. EPR coupled with release based on the tumor microenvironment or an external stimulus offers some solution to healthy tissue damage and has been demonstrated across nanomedicine to be effective. Many of these functionalities are applicable to VLPs that can be further modified to increase targeting specificity. Active targeting of a drug delivery system allows for the preferential accumulation into specific cells that can be selected for by a variety of tumor markers, such as small
peptides and antigens as well as cell surface receptors and biomarkers. These moieties have been used throughout the literature to up the chances of delivery to maligned cells—sparing the healthy ones. In an effort to increase specificity in delivery, targeting molecules have been employed such as folic acid or small peptides like cyclic RGD. For instance, Stephanopoulos et al. has constructed an MS2 capsid where they have attached aptamers specific to Jurkat leukemia T cells onto engineered p-aminophenylalanine (paF) groups followed by the conjugation of porphyrins on onto the interior cysteines that generate reactive oxygen when irradiated with blue light (Fig. 11.11). Approximately 20 aptamers were attached per capsid increasing the targeting specificity of the VLP. This dual-modal delivery system was shown to localize only in the Jurkat cells when cocultured with other cells and successfully and selectively initiated apoptosis through photoredox ROS generation.

11.5 Vaccines
Vaccines are continually used as a method of disease treatment and prevention since their inception by making use of inactivated native viral proteins to bolster our immune systems against foreign bodies. VLPs—lacking their viral genome—produce similar immune responses to those of native, infectious diseases. The highly organized structure of the VLP surface presents several repeating amino
acid sequences which can cross-link B-cell receptors which, in turn, quickens the activation of antibody responses. In addition, the encapsulated genome itself is capable of activating toll-like receptors and further eliciting an immune response with the added benefit of including a customized genetic cargo. Several VLP-based vaccines, such as human papilloma virus (HPV) and hepatitis B, are already on the market, but many more are under development. The Bachmann group has conducted extensive work utilizing the Qβ VLP to study its immunogenicity showing that the particle alone can transport a therapeutic while behaving as an adjuvant all in one by developing vaccines for influenza, respiratory allergies, and smoking cessation, reporting as much as 100% antibody response after inoculation of free Fel d1 indicating successful immune memory without adverse effects. This is an important step forward in the medical field as they have shown that VLP-based vaccines may be used as a safe, effective, and customizable method to produce vaccines.

VLPs offer many advantages to biological applications. In this chapter, we have discussed some of the important characteristics of VLPs that can be harnessed to advance biomedical fields such as imaging, sensing, and drug delivery. There are still some issues in using VLPs in biomedical applications, in particular they are immunogenic, which means repeated exposure will change the

**11.6 Conclusion**

VLPs offer many advantages to biological applications. In this chapter, we have discussed some of the important characteristics of VLPs that can be harnessed to advance biomedical fields such as imaging, sensing, and drug delivery. There are still some issues in using VLPs in biomedical applications, in particular they are immunogenic, which means repeated exposure will change the
pharmacokinetics in individual patients. This drawback is not unique to VLPs and is an issue for polymers as well.\textsuperscript{177,178} In context of cost, they will be more expensive than synthetic nanomaterials, though they are expressed in \textit{Escherichia coli} in high yields, which would make their eventual scale up in a process setting relatively practical. In imaging applications, the large size of VLPs is helpful in attaching a substantial amount of dye or contrast agent, and monodisperse subunits reduce self-quenching for high-resolution imaging. The functionalizability of VLPs owed to their multivalent subunits can also be used to increase bioprobe sensitivity while maintaining stability of the conjugate. Lastly, the biocompatibility and encapsulating ability of VLPs for drug delivery helps encourage the accumulation of drugs in a specified region with reduced clearance. Because VLPs are relatively new nanocarriers, the extent of the benefits they offer for biomedical applications has yet to be realized.

References


Chapter 11

Virus like particles


75. Kushnir N, Streat.


Nanoparticles for Biomedical Applications


113. Merbach, A.; Helm, L.; Töth, É. 2013; p 0.


